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Abstract 
Objectives Sleep deficiency is implicated in long-term sick leave and is found to 
frequently co-occur and interact with both mental disorders and physical illness. Higher 
prevalence of sleep deficiency in clinical populations compared to the general population 
indicates a complex relationship between sleep and disease. A dysfunctional HPA-axis has 
been associated to conditions like depression, anxiety and chronic fatigue syndrome. This 
study used elevated evening cortisol levels as a predictor for sleep deficiency.  
Methods Saliva cortisol measures were assessed in a heterogeneous patient population 
on long-term sick leave (N = 44). The participants were diagnosed with depression, anxiety 
and/or chronic fatigue syndrome. Saliva cortisol was collected on two consecutive days at 
awakening, +30 min (CAR) and at 22:00. Multiple logistic regression were used to measure 
potential risk factors for sleep deficiency. 
Results Mental health (anxiety and depression) was a strong risk factor for sleep 
deficiency. The study did not find a significant relationship between elevated evening 
cortisol levels and sleep deficiency. CAR-to-evening cortisol slope was not significantly 
different in patients diagnosed with depression, anxiety or chronic fatigue. 
Conclusion This study replicates previous studies demonstrating that anxiety and 
depression, both comorbid and independently, are significant risk factors for sleep 
deficiency. No relationship was found between elevated evening cortisol levels and sleep 
deficiency.   
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1. Introduction 
 
Sleep deficiency is common in Norway with 11.7 % of the population meeting the 
clinical criteria for an insomnia diagnosis [1]. Insomnia is one of the most common sleep 
disorders [2] and is defined as difficulties initiating or maintaining sleep, experiencing early 
morning awakenings and decreased daytime functioning for no less than 1 month [3–6]. Sleep 
problems are a major health complain and a common reason for medical consultations in 
Norway [7]. According to the 2011 update of the National Institutes of Health (NIH) Sleep 
Research Plan [8], the term sleep deficiency is characterized as an inadequate quantity or 
quality of sleep obtained for optimal wellbeing, performance and health [8,9]. Sleep 
deficiency may occur from sleep deprivation, sleep disorders, insufficient sleep duration or 
poor sleep quality [10].    
Norway has the highest rate of sickness absence in the OECD [11] and with around 90 
recognized sleep disorders, serious health effects may arise as consequences of inadequate 
sleep [12,13]. Sleep deficiency have been implicated in long term sick leave [14] and is linked to 
stress [15], psychological distress [16] and somatic disease [17]. Research show that sleep 
problems frequently co-occur and interact with both mental disorders and physical illness 
[3,5,18]. Furthermore, higher prevalence of sleep deficiency in clinical populations compared to 
the general population indicates a complex relationship between sleep and disease [19].  
Homeostatic imbalance could potentially lead to sleep deficiency [20]. Furthermore, 
sleep problems like insomnia symptoms have been found to predict sick leave [21], and is 
associated with activation of the hypothalamic-pituitary-adrenal (HPA) axis [13]. The 
relationship between sleep and stress is critical in insomnia [3]. Prior research have found 
that insomniacs have higher evening cortisol levels after stress exposure than healthy 
controls [22]. In addition, sleep deprivation is strongly linked to elevated evening cortisol 
levels  [23–25]. Elevated evening cortisol levels have been shown to indicate sleep deficiency 
[26] and alterations of the HPA-axis [27].  
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1.1. Stress - allostasis and allostatic load 
 
Homeostasis, the process of maintaining  a complex dynamic equilibrium, is 
constantly challenged by internal and external stressors [28]. Thus, stress can be defined as a 
state of threatened homeostasis where adaptive responses are needed in order to re-
achieve a balanced state [29]. Because we often encounter environmental conditions 
requiring our urgent attention and reactions, it has been theorized that the burden of 
chronic stress could enhance adaptive responses in the body called allostasis [23]. Allostasis 
provide compensatory feedback during stress in order to re-achieve the state of homeostasis 
[30,31]. Disrupted sleep is known to enhance physiological stress [32] which is something that 
has been seen in individuals with depression and/or anxiety [33].  
Chronic stressors could activate pathological mechanisms in the human body 
referred to as allostatic load [34,35]. It is also known that chronic activation of the HPA-axis 
may contribute to allostatic load by abnormal activation levels, further targeting brain 
structures like the amygdala in which behavioral changes may enhance fear and anxiety 
[36,37]. Studies on chronic stress in animal models have demonstrated neuronal hypertrophy 
(dendritic growth) in the amygdala which is believed to affect fear and anxiety  [23,37].  
The mechanisms of allostatic load describe how long-term exposure to chronic stress 
(seen as fluctuations or heightened neural and neuroendocrine responses), can lead to 
disease by an inefficient management of the structures promoting adaptation or by stress 
itself [35,38].  
 
1.2. Mechanisms of stress – the HPA-axis 
The HPA-axis can be described as a regulatory system connecting the central nervous 
system (CNS) with the endocrine system [39].  The hypothalamus, the pituitary gland and the 
adrenal cortex are the main parts of the HPA-axis. Corticotropin releasing hormone (CRH) is 
released from the hypothalamus and transported via the portal vessels to the anterior 
pituitary. Vasopressin (AVP) is found in some CRH-cells in the hypothalamic paraventricular 
nucleus (PVN) [40]. This nucleus is also the location for CRH production [40]. AVP act in 
combination with CRH to potentiate adrenocorticotropic hormone (ACTH) secretion into the 
bloodstream [42,43]. The main target of ACTH is the adrenal cortex, a site that regulates 
cortisol release by the adrenal zona fasciculata [44]. The HPA-axis itself is adjusted by a 
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negative feedback regulation of cortisol on the secretion of CRH and ACTH [45]. This 
regulation is known to reduce the prolongation of cortisol release as it helps maintain a 
pulsatile and circadian secretion  [44,46]. A weakened negative feedback regulation could lead 
to an inadequate suppression of CRH and AVP, and possibly result in elevated cortisol levels  
[47]. HPA-axis hyperactivity is strongly associated with sleep deficiency [48], and a vast majority 
of research on both humans and rodents indicate that a dysfunctional HPA-axis could 
increase sleep disruptions [22,49]. 
The HPA-axis is a central component in an individual’s stress response. In rats, CRH 
has been found to influence HPA-activity [50].  Timpl et al. (1998) [51] found a reduction in the 
release of ACTH and corticosterone in mice lacking a specific type of CRH receptor (Crhr 1).  
A crucial aspect of the stress response is that it is only intended to operate for a 
limited period of time. Chronic stressors could accelerate an enhanced system-activation, 
something that is considered to be a fundamental concept in the generation of stress-
enhanced pathology [29]. It is known that hypo- or hyperactivity of the pituitary- adrenal 
interaction could lead to alterations of the nervous system [52]. Increased sympathetic 
nervous system activity could have an effect on ACTH and on the adrenal glands which could 
further enhance the elevation of cortisol secretion [53]. Hyperactivity of the HPA-axis is 
associated with psychiatric disorders and clinical syndromes such as depression and 
insomnia, respectively [54,55].  
Increased cortisol secretion in humans, and corticosterone in rats, have been 
associated with behavioral deficits like depression [56–58] and anxiety [59–62]. Depressed 
patients are also at increased risk for hypercortisolism compared to the general population 
[63]. Intravenous injections of CRH have an effect in healthy individuals that is similar to the 
pattern observed in hypercortisolemic depressive patients [64].  The overactive state of 
hypercortisolism could be attributable to a defective feedback regulation [65,66]. According to 
Carroll et al. [67] depressive hypercortisolism could emerge from adrenal cortex dysfunction 
in which cortisol secretion acts independently from ACTH resulting in irregular cortisol 
secretion.  
Another condition associated with alteration of the HPA-axis is chronic fatigue 
syndrome (CFS). This condition is characterized by severe exhaustion and a combination of 
symptoms, particularly somnolence and both physical and mental fatigue [68,69]. It is 
estimated that 20-25 % of individuals diagnosed with stress-related disorders, such as CFS, 
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experience hypocortisolism [70]. Individuals diagnosed with CFS could be characterized as 
having a heightened negative feedback regulation [71] and a hyporesponsiveness on the 
various levels of the HPA-axis [70]. In addition, they commonly display a flattened  circadian 
cortisol cycle [71–74]. A dysfunctional cortisol signaling, such as found in CFS, could be a result 
of a declined hormone bioavailability and/or decreased hormone sensitivity [75].  
 
1.3. The relationship between stress and sleep 
The stress response is adjusted by the central nervous system (CNS) and other 
peripheral organs. Two essential components of the response are CRH and the locus 
coeruleus-norepinephrine systems [76,77] , both contributing with notable physiological 
responses to stress [78]. As the main regulator of the HPA-axis, CRH could influence stress-
induced changes in sleep by increasing insomnolence [79]. This could be a possible reasons to 
why CRH is so strongly associated with sleep deficiency [80,81]. Cortisol is suggested to have a 
modulatory effect on sleep [82]  A distinct increase of CRH in the limbic system and pituitary 
of sleep deprived rats could influence behavior alterations and sleep-regulation [83,84]. Rats 
limited to 4 hours of sleep for an 8-day period showed increased ACTH and glucocorticoids 
(corticosterone) concentrations [85]. Other studies have also reported similar findings, 
indicating sleep loss to be a likely cause behind increased ACTH and cortisol levels [80,86,87].  
It is important to focus on the complex reciprocal relationship between stress and 
sleep, considering that one third of the population will experience sleep problems at some 
time in their life [88]. A dysfunctional HPA-axis is strongly associated with sleep deficiency 
[89,90] and studies have indicated a positive correlation between poor sleep and HPA-axis 
activity in chronic insomniacs [48,91].  
 
1.4. The link between sleep deficiency and evening cortisol levels 
Cortisol secretion follows a pulsatile pattern, characterized by a relatively high 
awakening level that continues to rise until it peaks at about 30 minutes after awakening. 
This peak is called the cortisol awakening response (CAR) and is followed by a decline 
throughout the day, before reaching nadir (i.e. lowest level) [92] at around midnight [93,94]. The 
diurnal cortisol pattern is relatively independent from sleep and environmental inputs [80], 
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and is regulated by the hypothalamic suprachiasmatic nuclei (SCN) [95], a structure enhancing 
wakefulness by generation of daytime alertness [96]. The state of sleep has an inhibitory 
effect on cortisol secretion [54] however increased nocturnal HPA activity (possibly from 
nocturnal awakenings), contribute to sleep deficiency and is strongly linked to elevated 
evening cortisol levels in both healthy individuals and insomniacs [26,97]. Prior research are 
not conclusive, however, one study did not find elevated evening cortisol levels in individuals 
reporting sleep problems during the previous four weeks [98].  
 
1.4.1. Evening cortisol levels in individuals with depression, anxiety and CFS 
It has been shown that depressed individuals have higher cortisol concentrations 
particularly around nadir compared to age-matched controls [55,99,100]. A study on the 
relationship between depression and cortisol levels revealed that participants with severe 
depressive symptoms had higher evening cortisol levels than those with mild or low 
depressive symptoms [101]. Similar findings were reported in a study where elevated evening 
cortisol levels were more common in patients with severe psychiatric disorders than in those 
with less severe disorders [102]. Grynderup et al. (2013) [103] conducted a study on depression 
and cortisol levels and found that a smaller difference between morning and evening cortisol 
levels could be a risk factor for depression.  
A positive relationship between anxiety and evening cortisol levels has been 
indicated in several studies [104–106]. However, Vreeburg et al. (2010) [107] found no such 
associations. In CFS, evening cortisol levels are typically reduced compared to healthy 
controls [74,108]. It is common for individuals with CFS comorbid with depression to display a 
pattern of evening hypocortisolism [74].  
 
1.5. Sleep, stress and sick leave 
Studies have shown that comorbid mental disorders are significant risk factors for 
sleep deficiency  [109–111]. Furthermore, sleep deficiency has been identified as a serious risk 
factor for long-term sick leave [21,112–114] and to have a major impact on stress [115,116]. Prior 
research have identified sleep disturbances as common manifestations of both depression 
and anxiety [117]. Sleep disturbance is defined as chronic sleep disruption, in which the latter 
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have been characterized as dysregulation of sleep homeostasis and sleep deficiency [8]. 
Mood disorders are found in one-third up to one-half of all patients with sleep deficiency 
[118], and depression, more than any other psychiatric disorder, is strongly linked to sleep 
problems [119]. Insomnia, and sleep problems in general, are therefore often found to co-
occur and interact with depression [112,120]. Because of such a strong interaction, the DSM-IV 
lists sleep problems as part of the clinical criteria for the diagnosis of depression [121]. 
Knudsen et al. (2013) [122] found that comorbid anxiety and depression were 
significant risk factors for sick leave. Another study showed that anxiety, more than 
depression, was identified as a crucial risk factor for sick leave [123]. 
 Individuals with CFS on long-term sick leave report poor and altered sleep [124,125]. 
Even though sleep alterations could influence the etiology of CFS, they are not believed to be 
the common reason behind daytime fatigue [126]. A dysfunctional stress response is often 
common in CFS where symptoms of emotional distress are typically manifested somatically 
instead of emotionally [127]. The main purpose of sick leave is to contribute economically to 
those affected by illness or disease. Sick leave is meant to promote recovery and for people 
to regain their work capacity [113]. Mental health problems constitute considerable health 
problems in the Norwegian workforce [128] 
Two common consequences from being on sick leave is experiencing depression and 
increased stress [129]. Moreover, a study conducted on patients’ daily life whilst on sick leave, 
revealed poor sleep to be a common consequence, mainly due to the situation of being 
absent from work [113]. The negative effects of long-term sick leave is therefore strongly 
linked to both sleep and psychological well-being [113]. This correlates with a recent study 
showing that return to work was associated with improved sleep [113]. By improving sleep 
one does not only increase the chances of returning to work, but improvement could also be 
crucial in the rehabilitation and prevention of sick leave due to other stress-related disorders 
[130]. The risk of having comorbid conditions (where insomnia co-occur with psychiatric and 
medical disorders) are significantly reduced by sleep improvement [111]. 
 A cross-sectional study demonstrated that those who reported troubles initiating 
sleep, maintaining sleep, or experienced early morning awakenings were more likely to have 
two or more health problems than those without these symptoms [111,131]. Undiagnosed 
comorbid conditions in patients on long-term sick leave could predict their work ability and 
extent of sick leave [132]. It has been suggested that insomnia, either as a primary diagnosis or 
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secondary to other illnesses, should receive a greater emphasis for clinical intervention in 
order to lessen the economic burden accompanying sick leave [21]. 
 
1.6. Aim 
The aim of the present study was to examine the effects of sleep deficiency, 
measured on Insomnia Severity Index (ISI) [133] in a heterogeneous patient population. We 
expect that patients with elevated evening cortisol levels would report higher levels of sleep 
deficiency regardless of any diagnosis. 
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2. Methods 
 
2.1. Sampling procedure 
From January to June 2012, 112 patients between 18-59 years of age were referred 
to Hysnes Vocational Rehabilitation Center by their general practitioners (GP) for a 3.5-week 
in-patient intervention. The patients had been on sick leave longer than 8 weeks due to 
musculoskeletal pain, fatigue and/or common mental disorders. The participants were asked 
upon admission if they would be interested in participating in a study while receiving the 
intervention. Participants were excluded if they did not define return to work as a personal 
goal, had a severe mental disorder (acute psychosis, an ongoing manic episode or suicidal 
ideation), were not able to communicate in Norwegian, or were pregnant. Participants met 
with a physician, a psychologist and a physical therapist at a designated out-patient clinic to 
be examined before participating in the intervention. Prior to this examination the 
participants filled out an extensive web-based survey provided by CheckWare™. This survey 
included measures of sleep problems, mental distress, fear-avoidance measures, fatigue and 
socio-demographics. 
A total of 44 participants, 9 men and 33 women (2 missing), between 22 to 60 years 
of age (M = 39.95, SD = 10.35) were included in the study. Demographic information 
including age, sex and BMI (weight and height) was assessed by questionnaire and at out-
patient clinic. 
 
 
2.2. Measures 
 
2.2.1. Depression and anxiety 
The Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I) [134] is a semi-
structured interview used to diagnose major mental disorders according to DSM-IV-TR [135].   
The SCID-I include obligatory questions where symptoms are rated in a categorical system 
before an algorithm is used in order to provide a final diagnosis [134]. The SCID-I was 
performed by a clinical psychologist at the out-patient clinic to assess the presence of 
individuals with a diagnosis of depression (n=9) and anxiety (n=5).  
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2.2.2. Psychological and somatic measures 
Sleep deficiency was measured by the Insomnia Severity Index (ISI) [133]. The ISI 
comprises seven items evaluating perceived insomnia severity in the previous two weeks 
[136]. The questionnaire assess sleep-onset, sleep maintenance, early and nocturnal 
awakenings, satisfaction with current sleep pattern, interference with daily functioning, 
recognizable impairments attributed to sleep problem, and level of concern caused by the 
sleep problem [133,137]. Each question is scored on a 5-point Likert scale (0-4) with a total 
range of 0-28 [133]. Scores 15-21 indicate moderate, clinically significant insomnia, and scores 
22-28 indicate severe, clinically significant insomnia [138]. This study uses a cut-off score of 
>14 which has shown to have optimal specificity (94%) and sensitivity (94%) [137].  Different 
versions of the ISI are available; patient, clinician, and significant others [139]. This study uses 
the patient (self-administered) version only. 
 Chronic fatigue was measured by the Chalder Fatigue Questionnaire [140]. The 
questionnaire assesses  symptoms of cognitive difficulties, sleepiness, tiredness, loss of 
interest, lack of energy, lack of muscle-strength and lack of endurance [140,141].  Each question 
is scored on a 4-point Likert scale (0-3) in which the response alternatives are scored 
bimodally, 0-0-1-1, with a total range of 0-11 [141]. In this study, the 11 item questionnaire, 
which has an internal consistency, measured by Chronbach’s alpha, of 0.89 was used [142]. 
The questionnaire was later revised to include two questions on duration and extent [143]. A 
cut-off indicating fatigue was a score of ≥5, with a duration of more than 6 months. This cut-
off has been validated for a Norwegian population [143]  
 
2.3. Cortisol sampling 
Saliva was collected at awakening, 30 minutes after awakening (CAR), and at 22:00 
hours. In order to control for cortisol variability, which are known to depend on day of the 
week[144], collection was conducted on two consecutive days; Tuesdays and Wednesdays or 
Wednesdays and Thursdays. A former study found no differences in cortisol values between 
Tuesdays-Thursdays [145]. All participants were told to avoid touching the cotton swab with 
their fingers when removing or inserting it into the sampling tube (SARSTEDT AG & Co, 
Salivette® Cortisol). They were further instructed to avoid caffeinated drinks, smoking, 
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physical activity and eating 1 hour prior to sampling. Written instructions were also provided 
along with the sampling tubes. All participants were told to keep the swab in the mouth for 1 
minute and to note the time of sampling on the instruction sheet. The samples were 
domestically stored in a refrigerated state during the collection period before they were 
further stored at minus 20 degrees C. At this temperature cortisol samples remain stable for 
9 months [146]. 
 
2.4. Cortisol analysis 
   The cortisol samples in the current study were analyzed within 7 months at the 
Department of Medical Biochemistry at St. Olavs Hospital, Trondheim. The assay used for 
determination of cortisol in saliva was Roche Modular E with an analytic variability of 7.9 % 
at 12 nmol/L.  
 
2.5. Statistical analysis 
All statistical analyses were conducted using R statistical software (R 
Development Core Team 2012) for Windows and IBM SPSS statistics 21 (SPSS Inc., Chicago, IL 
USA) for Windows.  
Participants with one or more missing CAR or evening measures were excluded from 
further data analysis. In addition, descriptive statistics were used to characterize basic 
features for each variable of interest. Mean awakening, CAR and evening values were 
cleaned in order to remove outliers (values > 3 standard deviations from the mean) [147]. 
Pearson product-moment correlation coefficients were used to measure the relationship 
between the two days of saliva collection, and we used the mean over the two collection 
days for further analyses [148]. Pearson product-moment correlation coefficients were also 
computed to assess the relationship between depression, anxiety and CFS.  
The diurnal cortisol rhythm was measured by the slope, as an indication of the rate of 
decline. We only included participants with valid CAR and evening samples for both days of 
saliva collection. The slope was calculated as the difference between CAR and evening 
cortisol levels in the valid saliva samples, and elevated evening cortisol levels (i.e. flat CAR-
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to-evening slope) was by determined by values >1 standard deviation above the mean 
cortisol slope. 
The associations between baseline characteristics and sleep deficiency (yes or no) 
were analyzed using students t-test for continuous variables: cortisol slope, evening cortisol 
levels, age, and BMI, or Fischer’s exact test for categorical variables: sex, depression, anxiety, 
and CFS. All statistical analyses in the current study operated with a p-value of <.05 to be of 
statistical significance.  
2.5.1. Regression analysis 
Logistic regression analysis was used to examine the relationship between sleep 
deficiency and elevated evening cortisol levels (i.e. flat CAR-to-evening slope). The following 
covariates (determined a priori based on known influence on saliva cortisol measures) were 
included in the analyses: age (continuous), sex (male, female), BMI (continuous), depression 
(yes, no), anxiety (yes, no) and CFS (yes, no).  
The main predictor variable of interest was elevated evening cortisol levels (a flat 
cortisol slope), while depression, anxiety and CFS together with age, sex and BMI were other 
covariates included in the analysis. The dependent variable, sleep deficiency, was 
dichotomized and results are presented as odds ratios (ORs) with 95% confidence intervals 
(CIs). In addition, the probability values (p-values) and the coefficient for the constants (Bs) 
together with the standard errors (SEs) are given.  
 
2.6. Ethics 
Participation was voluntary and all participants provided written informed consent. 
The study was approved by the Regional Committees for Medical and Health Research Ethics 
(REC) and conducted in accordance with the Declaration of Helsinki. 
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3. Results 
 
3.1. Descriptive statistics 
 From a total of 44 participants, 19 (43 %) reported sleep deficiency, 6 (16 %) had 
elevated evening cortisol levels, 9 (21 %) were diagnosed with depression, 5 (12 %) were 
diagnosed with anxiety and 31 (74 %) were diagnosed with CFS.  Table 1 provides an 
overview of the participant characteristics listed by the presence or absence of sleep 
deficiency. 
 
Table 1     Participant characteristics and their association between the presence or absence 
of sleep deficiency. The level (SD), frequency (%) or mean (SD) are listed together with the p-
value for the association.  
                          Sleep deficiency   
Characteristic        Yes (n=19)      No (n=25) p-value 
Cortisol slope CAR-to-evening, nmol/L, mean (SD) 
   
     1. Flat -8.33 (.58) -8.33 (1.15) .54 
     2. Not flat -18.57 (4.85) -18.77 (7.31) .93 
Evening cortisol levels, nmol/L, mean (SD) 7.08 (2.27) 6.91 (2.22) .81 
Age in years, mean (SD) 39.1 (11.8) 40,5 (9,2) .66 
Sex 
        1. Male 3 (33.3 %) 9 (66.7 %) 
.47 
     2. Female 16 (48.5 %) 17 (51.5 %) 
BMI, kg/m², mean (SD) 26,9 (4,2) 27,0 (5,4) .96 
Depression 
        1. Yes 8 (88.9 %) 1 (11.1 %) 
.00 
     2. No  11 (31.4 %) 24 (68.6 %) 
Anxiety* 
        1. Yes 5 (100 %) 0 (0 %) 
.01 
     2. No 14 (36.8 %) 24 (63.2 %) 
CFS** 
        1. Yes 15 (48.4 %) 16 (51.6 %) 
.73 
     2. No 4 (36.4 %) 7 (63.6 %) 
Significant P-values are bolded (p<.05); *Anxiety data missing on one participant; **Chronic fatigue data missing on two 
participants.  
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Descriptive statistics revealed that 3 participants were diagnosed with all three 
conditions; 3 participants were diagnosed with depression and anxiety; 3 participants were 
diagnosed with CFS and depression, and 4 participants were diagnosed with CFS and anxiety. 
Correlation coefficient revealed a significant relationship between depression and anxiety 
(r=.35, p<.05).  
Sleep deficiency was not associated with mean evening cortisol levels or CAR-to-
evening slope. Looking at the covariates, neither age, sex nor BMI were associated with 
sleep deficiency.  
Sleep deficiency was, however, significantly associated with both depression and 
anxiety. These findings indicate that depression and anxiety are independently associated 
with a greater prevalence of sleep deficiency (p<.05). CFS, however was not associated with 
sleep deficiency. The CAR-to-evening cortisol slope in CFS was not significantly different from 
the slope in the other two conditions. 
 
3.2. Cortisol values 
From the cortisol samples returned, 14 samples were not taken by the participants 
leaving a total of 249 individual samples. In order to examine for normality and control for 
measurement inaccuracies, all cortisol values were checked for outliers. After removal of 5 
outliers the cortisol data showed a normal distribution so there was no need for 
transformations. 
Correlations coefficients between the two consecutive days of saliva collection 
indicated positive correlations between the two awakening (r=.45, p=<.01), and CAR (r=.75, 
p=<.01) measures, but not between the two evening (r=.23, p=.14) measures. Average 
cortisol values for the two consecutive days of saliva collection are shown for participants 
with sleep deficiency (Figure 1) and without sleep deficiency (Figure 2). 
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Figure 1 Average cortisol values for participants with sleep deficiency. Saliva concentration at awakening, CAR (+30 min) 
and evening (22:00 h) are shown. 
 
 
 
Figure 2 Average cortisol values for participants without sleep deficiency. Saliva concentration at awakening, CAR (+30 
min) and evening (22:00 h) are shown. 
 
 
3.3. Cortisol slope 
In order to identify participants with elevated evening cortisol levels we calculated 
the slope from CAR to evening. Mean CAR cortisol value was 21.8 nmol/L based on 79 
individual values, and mean evening cortisol value was 6.9 nmol/L based on 84 individual 
values. The average CAR-to-evening cortisol slope was -16.5 indicating a decline throughout 
the day.  
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3.4. Regression analysis 
Multiple regression analyses were conducted to examine the relationship between 
sleep deficiency and various potential predictors. The analyses revealed that mental health 
(depression and anxiety) was the strongest predictor of sleep deficiency, whereas evening 
cortisol levels, age, sex, BMI and CFS showed more inconsistent relationships.  
The results did not reveal a significant main effect of having a flat CAR-to-evening 
slope on sleep deficiency. Specifically, a flat CAR-to-evening slope (i.e. elevated evening 
cortisol levels) was not associated sleep deficiency (OR 1.07, 95% CI: .19-6.13). In addition, a 
non-flat CAR-to-evening slope (i.e. not having elevated evening cortisol levels) was not 
associated with sleep deficiency (OR .94, 95% CI: .16-5.39; data not shown). Table 3 
summarizes the results.  
 
Table 3.     Summary of multiple regression analysis for the potential predictors of sleep 
deficiency.  
                    95 % CI for OR 
Variable               B (SE)        P-value               OR       Lower         Upper 
Flat CAR-to-evening slope .06 (.89) .94 1.07 .19 6.13 
Age 
 
-.01 (.03) .65 .99 .93 1.05 
Sex 
 
.63 (.79) .42 1.88 .40 8.82 
BMI 
 
-.01 (.06) .92 .99 .88 1.12 
Depression 
 
2.86 (1.12) .01 17.45 1.94 157.20 
Anxiety* 
 
∞ (∞) .01 ∞ 1.32 ∞ 
CFS .49 (.72) .49 1.64 .40 6.76 
*Fischer’s exact test used instead of logistic regression due to small sample size. All participants with anxiety (n=5) reported 
sleep deficiency. 
 
The results indicate significant main effects of depression and anxiety on sleep 
deficiency. Specifically, they were both independently associated with a flat CAR-to-evening 
slope. However, because all participants diagnosed with anxiety reported sleep deficiency, 
accurate calculation in the regression model was not performed. Instead, Fischer’s exact test 
was used with results indicating an OR of infinity (Table 3).  
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4. Discussion 
The goal of the current study was to examine the effects of sleep deficiency, measured 
on Insomnia Severity Index (ISI) [133], in a heterogeneous patient population. We expected 
that patients with elevated evening cortisol levels would report higher levels of sleep 
deficiency regardless of any diagnosis. 
This study did not find that self-reported sleep deficiency was associated with 
elevated evening cortisol levels in participants diagnosed with depression, anxiety or CFS on 
long-term sick leave. Thus, the hypothesis that patients with elevated evening cortisol levels 
would report higher levels of sleep deficiency, regardless of diagnosis, was not supported. 
The results from the current study contrast prior research on the effects of sleep on 
evening cortisol levels [27,97,149]. For example, Rodenbeck et al. (2002) [97] found alterations in 
HPA-activity in participants with sleep problems. Moreover, insomnia and sleep deprivation 
have been linked to hyperactivity of the HPA-axis [89], and increased evening cortisol levels, 
respectively [23].  
Because an essential aim of sleep is to restore depleted energy levels [12], and 
because sleep is such a fundamental component of human homeostasis [150] we expected 
participants reporting sleep deficiency to display an abnormal HPA-activation. Our study did 
not support HPA-axis dysfunction to be associated with sleep deficiency [89,90].  
It is known that glucocorticoids could influence stress and brain functioning, and that 
a dysfunctional HPA-axis could lead to increased saliva cortisol concentration [151]. The latter 
has been found to indicate depression [152], however no such association was found in the 
current study. Consistent with prior research on comorbidity and sleep, our results indicate 
that comorbid mental disorders were significant risk factors for sleep deficiency [109–111]. 
Breslau et al. (1996) [153] found a strong association between depression and sleep 
disturbances, and that sleep disturbance per se, could signal an increased risk for the onset 
of depression.  
A prior study conducted by Grynderup et al. (2013) [103] found that a small difference 
between cortisol levels in the morning and evening could be a potential risk factor for 
depression. Even though depression was significantly related to sleep deficiency in our 
study, it was not related to elevated evening cortisol levels.  
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The current study did not reveal a significant relationship between CFS and sleep 
deficiency, nor did it indicate hypocortisolemia in CFS [74]. Interestingly, the majority of 
participants with CFS in our study reported having sleep deficiency, but the relationship with 
elevated cortisol levels were not statistically significant. Nater et al. (2008)[154] found that 
CFS is associated with a weak reduction in cortisol concentration across the day, and that 
this decreased diurnal cortisol variation is significantly different from the pattern found in 
healthy controls [72]. This pattern could also be indicative of a flattened diurnal cortisol 
rhythm, but our results found no significant difference between the cortisol slope in CFS and 
the other two conditions.  
Neuroendocrine dysfunction, often reported in CFS, could occur as consequences of 
sleep disruptions [155]. CFS is typically associated with low evening cortisol levels [108] and 
many individuals with the condition display a flattened circadian cortisol cycle [154].  Our 
study did not find a flattened CAR-to-evening slope in patients diagnosed with CFS. We 
speculate whether comorbidity and/or light symptomatology could be potential reasons as 
to why the cortisol slope was similar in CFS and the other conditions.  
Hansen et al. (2012) [98] did not find  any relationship between sleep problems and 
morning-to-evening cortisol slope in CFS, but at follow up three months later, those with 
sleep problems displayed a flattened cortisol profile [98]. This suggests that a follow up could 
have been used in the current study to capture potential changes in cortisol secretion.  
Even though the results were not significant, the OR for age, sex and BMI revealed 
that only sex had an effect on sleep deficiency indicating that being female was associated 
with an increased risk for sleep deficiency.   
A major strength in this study is the use of cortisol secretion measured in saliva [156]. 
Many studies have used saliva sampling [157–160] because it is a non-invasive, reliable 
technique, used for determining adrenal cortical activity [94]. Another major strength was the 
implementation of SCID-1 as a diagnostic tool to diagnose individuals with depression and 
anxiety.  
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4.1. Limitations  
The analyses in the current study were not adjusted for comorbidities other than 
simple descriptive statistics between the conditions of interest. Nor did the study control for 
symptom severity in depression, anxiety or CFS and could potentially have missed significant 
results in those with more severe symptomatology.    
The study did not quire about participants’ stress level during the days of saliva 
collection. Because insomniacs are known to have higher evening cortisol levels after stress 
exposure than healthy controls [22] a diary study of self-reported stress during the collection 
days could potentially control for external influences. The logistic regression model was 
unstable due to a predictor variable with a distribution of zero counts in one cell. 
Even though the relationship between depression and anxiety was strongly 
significant one could argue that the correlation is weak considering only 5 participants were 
diagnosed with anxiety. The study population was not homogenous and a relatively high 
comorbidity rate was observed in the anxiety condition were 4 out of 5 of participants 
diagnosed with anxiety also reported CFS. Any inferences made must be interpreted with 
caution due to a small sample size. Future studies could include larger samples, particularly 
for a potential anxiety population. 
In general, the coefficients should be no less than twice the size of its standard error 
to be of statistical significance [161]. Looking at the coefficient for the constants, only 
depression and anxiety revealed coefficients of significance, the latter being reported as 
infinity. Another limitation is the large confidence interval obtained for depression and 
anxiety. Larger studies have the ability to potentially offer more precise estimates of effect, 
and the ability to obtain narrower confidence intervals [162].  
Multilevel modelling could have been used in order to examine possible relationships 
between the variables of interest and cortisol levels. Hruschka et al. (2005) [163] describe how 
multilevel modelling have the ability to model variation between- and within individuals.  
No significant relationship was found between the two evening measures of the two 
consecutive days of two days of saliva collection. 
To conclude, the current study did not support the hypothesis that elevated evening 
cortisol levels were a risk factor for sleep deficiency.  Mental health (anxiety and depression) 
was a strong risk factor for sleep deficiency. The study did not find a significant relationship 
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between elevated evening cortisol levels and sleep deficiency. CAR-to-evening cortisol slope 
was not significantly different in patients diagnosed with depression, anxiety or chronic 
fatigue. 
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